retatrutide phase 3 trials Shows 28.3% Weight Loss in Obesity Trial First Retatrutide phase 3 data,

Neither Cagrilintide nor Retatrutide should be used without medical supervision

The limited number of patients using Mounjaro off-label for obesity is roughly on par with Ozempic persistence for type II diabetes, hovering around 45% at month 12

The upregulation of GLP-1 positive cells might be linked to an increase in GLP-2, an L-cell-derived peptide and a further splice product of the gcg gene

These medications mimic the natural GLP-1 hormone that helps regulate appetite, blood sugar levels, and digestion

More broadly, anyone seeking treatment for obesity or type 2 diabetes should be aware that NICE-approved treatment pathways exist in the UK, including licensed medicines with established safety profiles, regulatory oversight, and clinical support structures

If you suspect an adverse reaction to Ozempic, you can report this through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk